Instrument Inactif

Autres langues PHARMING GROUP Euronext Amsterdam

Actions

NL0000377018

Produits pharmaceutiques

Cours en clôture Euronext Amsterdam
- ^EUR	-

29/09	Pharming nomme Leverne Marsh et Kenneth Lynard au poste de co-directeurs généraux	MT
29/09	Départ du directeur général de Pharming Group

Autres langues

29/09	Vertrek CEO Pharming creëert onzekerheid
29/09	Pharming Appoints Leverne Marsh, Kenneth Lynard as Co-CEOs
29/09	Pharming Group CEO Steps Down; Interim Co-CEOs Named
29/09	Pharming op zoek naar nieuwe CEO
29/09	Pharming announces CEO transition
29/09	Pharming Group N.V. Announces CEO Changes, Effective September 29, 2026
29/09	Pharming Group N.V. Announces Stepping Down of Fabrice Chouraqui as Executive Director, Effective September 29, 2026
27/09	Chippers en chemie bieden Damrak steun
25/09	Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case
25/09	Pharming Says FDA Accepts sNDA for Lower-Dose Joenja in Children With APDS
25/09	Pharming Group N.V. Announces U.S. FDA Acceptance And Priority Review Of sNDA For Lower Doses Of Joenja To Treat Children With APDS
25/09	FDA gaat aanvullende aanvraag Pharming voor Joenja versneld beoordelen
25/09	Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
22/09	Pharming meldt goed nieuws voor Joenja
22/09	Pharming Group N.V. Announces Positive Phase II Topline Data For Leniolisib In PIDs With Immune Dysregulation Accepted As Late-Breaking Abstract At ESID 2026
22/09	Pharming presenteert spoedig nieuwe studieresultaten met leniolisib
22/09	Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
14/09	FDA approves Pharming's Joenja(R) as first treatment for children with APDS in the U.S.
14/09	Pharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja
11/09	Pharming Receives Fda Approval for Joenja as First Treatment for Children with Apds in the U S
11/09	Pharming krijgt goedkeuring FDA voor nieuwe indicatie Joenja
11/09	FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
11/09	Pharming Gets FDA Approval for Joenja to Treat APDS in Children Aged 4-11
11/09	Pharming krijgt goedkeuring FDA voor nieuwe indicatie Joenja
09/09	Pharming Group to participate in September investor conferences